Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Viloxazine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Adverse reactions; Registrational
Sponsors Supernus Pharmaceuticals

Most Recent Events

17 Jan 2024 Status changed from active, no longer recruiting to completed.
10 Jun 2022 Results presented at the 175th Annual Meeting of the American Psychiatric Association
08 May 2021 The study protocol was amended to change timeframe of endpoints from 2-4 week to up to 156 weeks. Maximum age amended to include patient up to 65 year of age.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com